We offer our registered users tailored information, free online courses and exclusive content.
Reset it here.
We offer our registered users tailored information, free online courses and exclusive content.
• analyse colorectal cancer biology and molecular biomarkers of clinical relevance
• review biomarker-driven therapeutic strategies in patients with metastatic colorectal cancer
• evaluate the essentials of continuum of care approach for patients with metastatic colorectal
cancer within a multidisciplinary team setting
Session I Molecular pathology and biomarkers
Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)
14.15 L1: Critical pathways in metastatic colorectal cancer (mCRC)
A. Sobrero (Italy)
14.45 L2: Molecular biomarkers for mCRC
A. Sobrero (Italy)
15.15 Coffee break
15.30 L3: Evidence-based recommendations for molecular testing of mCRC
C.H. Köhne (Germany)
16.00 ROUNDTABLE: Key guidelines questions
J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)
16.30 L4: Tumor heterogeneity and blood-based biomarkers
J. Taieb (France)
17.00 Closing remarks
17.15 End of the first day
Session II Treatment decisions in metastatic colorectal cancer (I)
Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)
09.00 L5: RAS Wild-type and BRAF Wild-type mCRC
A. Sobrero (Italy)
09.30 L6: Primary tumor location of RAS wild-type mCRC: left vs right
C.H. Köhne (Germany)
10.00 WORKING GROUPS: Clinical cases discussion
J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)
10.30 Coffee break
10.45 L7: RAS mutated and BRAF mutated mCRC
J. Taieb (France)
11.15 ROUNDTABLE: Frontline Strategies for Metastatic Colorectal Cancer
J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)
12.15 WORKING GROUPS: Clinical cases discussion
J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)
13.00 Lunch
Session III Treatment decisions in metastatic colorectal cancer (II)
Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)
14.00 L8: Oligometastatic disease
C.H. Köhne (Germany)
14.30 L9: Therapy after progression
J. Taieb (France)
15.00 WORKING GROUPS: Clinical cases discussion
J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)
15.30 L10: Spotlight - Molecular classification of CRC
C.H. Köhne (Germany)
15.45 L11: Spotlight - Immunotherapy for mCRC
J. Taieb (France)
16.00 Concluding remarks
End of the workshop